Diamond Investment Announces Board Approval to Lift Manager's Non-Compete Restrictions

1. Board Resolution Date: July 3, 2026 (R.O.C. Year 115) 2. Name and Title of Manager Permitted to Engage in Competitive Activities: Lu Kong-Ming, General Manager 3. Approved Competitive Activities: (1) Chairman of Diamond High-Tech Investment Co., Ltd. (2) Chairman of Diamond No.1 Investment Co., Ltd. (3) Chairman of Elite Investment Co., Ltd. (4) Chairman of Newshine Biotech Investment Co., Ltd. (5) Director of Zhongtian (Shanghai) Biotechnology Co., Ltd. (6) Director of Zhongtian (Hong Kong) Biotechnology Co., Ltd. (7) Legal Director Representative of Megabio Inc., (HK) Limited (8) Director of Microbio Pharmaceutical Co., Ltd. (9) Chairman of Oneness (USA) Biotech Inc. (10) Vice Chairman and CEO of Evergreen Biotech Co., Ltd. (11) Chairman and General Manager of Taiwan Everlife Cell Co., Ltd. 4. Duration of Approval: Throughout the manager's tenure at the company 5. Resolution Outcome (per Article 32 of the Company Act): Approved unanimously by all attending directors. 6. Manager's Name and Title for Approved Competitive Activities Involving Mainland China Operations (Enter 'Not Applicable' if not applicable): Lu Kong-Ming, General Manager 7. Company Name and Position Held in the Mainland China Entity: Director, Zhongtian (Shanghai) Biotechnology Co., Ltd. 8. Address of the Mainland China Entity: No. 1188 Guangxing Road, Songjiang District, Shanghai 9. Business Scope of the Mainland China Entity: Pharmaceutical manufacturing, contract pharmaceutical manufacturing, pharmaceutical wholesale, and technical development, transfer, consultation, and services within the fields of medicine, food, and health technology 10. Impact on the Company's Financial and Business Operations: None 11. If the Manager has invested in the Mainland China Entity, the Investment Amount and Shareholding Ratio: (1) Investment Amount: 5.705 million USD (2) Shareholding Ratio: 10.88% 12. Other Matters to be Disclosed: None